Progenics Pharmaceuticals Inc. (PGNX): Earnings News

PGNX – Beats EPS loss estimates by $0.19 and beats on revenues.

Key Facts Surrounding This News Item

  • PGNX had a POWR Rating of C (Neutral) coming into today.
  • PGNX was 7.91% above its 10-Day Moving Average coming into today.
  • PGNX was 16.88% above its 20-Day Moving Average coming into today.
  • PGNX was 17.48% above its 50-Day Moving Average coming into today.
  • PGNX was 20.09% above its 100-Day Moving Average coming into today.
  • PGNX was 14.53% above its 200-Day Moving Average coming into today.
  • PGNX had returned +21.34% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.

More Info About Progenics Pharmaceuticals Inc. (PGNX)

Progenics Pharmaceuticals is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. The company was founded in 1986 and is based in Tarrytown, New York. View our full PGNX ticker page with ratings, news, and more.

Try Premium Today!

Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

PGNX at a Glance

PGNX Current POWR Rating™
Overall POWR Rating™
PGNX Current Price $6.41 2.44%
More PGNX Ratings, Data, and News

PGNX Price Reaction

The day of this event (Mar. 8, 2018)
PGNX Closing Price$8.32 15.24%
PGNX Volume5,444,900
409.62% from avg
Leading up to this event
PGNX 1-mo return34.95%
After this event
PGNX 1-day return10.86%
PGNX 3-day return12.80%
PGNX 5-day return13.01%

PGNX Price Chart

More Progenics Pharmaceuticals Inc. (PGNX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All PGNX News
Page generated in 1.425 seconds.